We are excited to bring forward Hauxton Meadows to provide much-needed premium laboratory space for scientific innovation. The Meadows is a next-generation 90,000 sq.ft life science research facility designed specifically for AI-enabled biotechnology companies while introducing flexible robotic laboratories that reduce operating costs and improve research productivity. Located in close proximity to the Cambridge Biomedical Campus, South Cambridge Station & University of Cambridge, the site is helpfully connected to academia, science parks and techbio clusters.

The future of drug discovery lies in the convergence of artificial intelligence, robotics and laboratory automation. As pharmaceutical companies seek to improve R&D productivity and timelines, investment is rapidly shifting towards self-driving Laboratories that integrate AI-driven experimental design with automated execution and continuous learning, also known as 'lab-in-the-loop'. Purpose-built to accommodate both hybrid and fully autonomous laboratory environments, The Meadows provides a future-ready platform for organisations developing the next generation of AI-enabled therapeutics.

ADC & Targeted Conjugate Discovery
Antibody-drug conjugates are rapidly becoming one of the most active areas of oncology drug discovery, driven by advances in linker chemistry, payload design and targeted delivery. Supporting these increasingly sophisticated programmes requires expertise across multiple scientific disciplines. At o2h Discovery, our capabilities span payload chemistry, peptide-based linker technologies and conjugation-ready building blocks, underpinned by medicinal chemistry, peptide synthesis and advanced analytical sciences. Bringing these capabilities together within an integrated workflow enables ADC and targeted conjugate programmes to progress more efficiently from concept through candidate selection.
 

Novel Biology
Human-relevant biology is becoming increasingly important in early drug discovery, providing models that better reflect disease biology and therapeutic response than conventional cell-based systems. Our Novel Biology platform is focused on advancing New Approach Methodologies (NAMs), including organoids, spheroids and organ-on-a-chip technologies, helping generate more predictive data earlier in the discovery process.
 

PR&D and Scale-up
Our integrated PR&D and Scale-up capabilities bridge discovery chemistry with process development, enabling efficient route optimisation, technology transfer and non-GMP manufacturing. Supported by purpose-built PR&D laboratories and a dedicated kilo lab equipped with 20 L, 50 L and 100 L jacketed glass reactors operating across a –45 °C to 250 °C temperature range, we help partners scale promising compounds safely, efficiently and with sustainability in mind, ensuring a smoother transition from discovery to development.
 

DMPK: Faster Turnaround, Deeper Integration
Generating the right ADME and pharmacokinetic data at the right stage can significantly influence downstream decision-making. As discovery programmes become increasingly data-driven, integrating DMPK earlier into the workflow is becoming essential rather than optional. Our dedicated DMPK laboratory has been established to provide that integration alongside medicinal chemistry and biology.

o2h Peptide Kickstarter
The o2h Peptide Kickstarter is an extended initiative to help early-stage biotech companies developing peptide therapeutics. Selected winners receive access to 100 high-purity peptides, up to 100 ADME data points, and up to six months of optimisation support to accelerate candidate progression. Participants can also access biology services at a 20% reduced cost to further advance their programmes. Check out the details here.
 

Co-discovery with Inflexion Therapeutics
InflexionTx combines flexible match funding with o2h Discovery's integrated scientific expertise to generate critical proof-of-concept data. By sharing scientific and financial risk, the initiative helps biotech companies validate promising ideas, overcome development hurdles and reach their next value inflection point.
Visit the official website here.

Our team was at the Global Conferences
Over the past few months, members of our team have been actively engaging with the global scientific community.

At o2h Discovery, we seed new ideas in life sciences through an integrated, AI-enabled co-discovery platform that brings together scientific expertise, novel capabilities and strategic partnerships to help accelerate promising science towards development candidates. With teams across Cambridge (UK), the USA and Ahmedabad (India), we're proud to support innovators at every stage of the drug discovery journey.

Whether you're advancing your next therapeutic programme, exploring a new partnership, or simply looking to start a conversation, we'd be delighted to connect.